New Delhi [India], October 21 (ANI): As India on Thursday crossed 100 crore COVID-19 vaccination, Bharat Biotech's Chairman and Managing Director Dr Krishna Ella said that the firm is proud to have contributed to this 'historic landmark'.
New Delhi [India], October 21 (ANI): As India achieved the milestone of vaccinating over 100 crore citizens on Thursday, we take look at the basket of vaccines developed, manufactured or in use in the country.
New Delhi [India], October 21 (ANI): Zydus Cadila's vaccine - ZyCoV-D is the first indigenously manufactured needle-free Covid-19 vaccine which is approved for children aged above 12 for emergency use in the country. Earlier, the Subject Experts Committee (SEC) has also recommended the Hy
Geneva [Switzerland], October 18 (ANI): World Health Organisation (WHO), which is reviewing the data provided by Bharat Biotech for Emergency Use Listing of COVID-19 vaccine Covaxin, said on Monday that it is "expecting one additional piece of information from the company today".
Geneva [Switzerland], October 17 (ANI): Dr Soumya Swaminathan, World Health Organisation (WHO) chief scientist on Sunday informed that WHO's technical advisory group will meet on October 26 to consider emergency use listing (EUL) for Hyderabad-based Bharat Biotech's COVID-19 vaccine Covax
New Delhi [India], October 16 (ANI): India will have a vaccine capacity of 28 crore doses this month, which includes 22 crore Serum Institute of India's Covishield and 6 crore doses of Bharat Biotech Biotech's Covaxin and production of 60 lakh Zydus Cadila's ZyCoV-D doses are also ready,
Bhubaneswar (Odisha) [India], October 15 (ANI): Foreign Secretary Harsh Vardhan Shringla on Thursday expressed hope that the World Health Organisation (WHO) will soon give approval to Hyderabad-based Bharat Biotech's COVID-19 vaccine Covaxin.
New Delhi [India], October 14 (ANI): The final approval for Bharat Biotech's Covaxin for children aged 2-18 years is under experts opinion and evaluation, stated Government sources on Thursday.
New Delhi [India], October 12 (ANI): The Subject Expert Committee (SEC) has given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's COVID-19 vaccine, Covaxin, for the beneficiaries aged between 2-18 years, the official sources said on Tuesday
New Delhi [India], October 12 (ANI): After the evaluation of data Covaxin is yet to get approval by the Drugs Controller General of India (DCGI) for children between 2-18 years old, according to official sources.
New Delhi [India], October 12 (ANI): Subject Expert Committee (SEC) has given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's COVID-19 vaccine Covaxin for the beneficiaries aged between 2-18 years, the official sources said.
Geneva [Switzerland], October 5 (ANI): World Health Organisation (WHO) has extended giving the emergency use authorization for Hyderabad-based Bharat Biotech's COVID-19 vaccine Covaxin to next week.